Sylvester Comprehensive Cancer Center

E-mail a Friend

Joseph D. Rosenblatt, M.D.

General Information

Joseph D. Rosenblatt, M.D.

Languages

  • English

Certifications

  • American Board of Internal Medicine
  • American Board of Internal Med-Medical Oncology

CV

Specialties

  • Hematology/Oncology - Internal Medicine
  • Internal Medicine

Roles

  • Professor of Medicine
  • William J. Harrington Chair in Hematology

Clinical Interests

Dr. Rosenblatt's clinical interests include hematologic malignancies, development of novel approaches to breast cancer and solid tumors, gene therapy and immunotherapy of cancer.

Research Interests

In the past 20 years, Dr. Rosenblatt's work focused on human retroviruses, immune therapies for cancer and human gene therapy. Current work is directed to development of novel immune therapy and gene therapy strategies for breast and other cancers. The lab investigates the potential role of recruitment of immune effector cells that elaborate constitutive and inflammatory chemokines on the development of an anti-tumor response and the role of chemokines delivered alone or in combination with expression of the costimulatory ligands CD80 (B7.1) or CD40L. Several delivery strategies have been investigated, including the use of use of Herpes Simplex virus amplicon vectors in several murine tumor models. The Herpes Simplex amplicons are also being tested for efficacy in augmenting the immunogenicity of malignant cells. Novel methods of immune effector molecule delivery, which involve delivery by antibodies of a costimulatory molecule, anti-angiogenic peptide or a chemokine are also under investigation. Antibody fusion proteins targeting the human breast cancer her2/neu antigen, linked to the extracellular domains of T-cell costimulatory ligands and /or chemokines have been synthesized and are being tested for their in vitro ability to bind to cognate antigenic targets and to deliver a local costimulatory signal or chemotaxis signal. A novel therapeutic, that fuses the anti-angiogenic peptide endostatin to anti-her2/neu antibody, shows excellent efficacy in preclinical models. Currently, Dr. Rosenblatt is using a novel B-cell deficient mouse model to test antibody fusion protein targeting to xenogeneic (e.g. CEA, her2/neu) antigens, while preserving T-cell immune effector functions. The B cell deficient model has also demonstrated enhanced TH1 T cell responses to tumor compared to those seen in the immunocompetent mouse.

Awards

Best Doctors in America
Emanuel G. Rosenblatt Award
Who’s Who in Medical Education
Best Doctors in America
Davey Memorial Award
Presidential Award
Research Award
Who's Who in America
Fellow
Shannon Award
Fullbright Scholarship
Leukemia Research Foundation Award
Cancer Research Award
University-Wide Task Force
Fellow
Cancer Research Award
President's Undergraduate Fellowship Award

Education

1986 Fellowship
UCLA - University of California, School of Medicine
1983 Residency
UCLA - University of California, School of Medicine
1980 M.D.
UCLA - University of California, School of Medicine
1976 B.S.
University of California

Publications

Biography

Joseph D. Rosenblatt, M.D., is the Interim Director of Sylvester Comprehensive Cancer Center, Professor of Medicine, and the William J. Harrington Chair in Hematology. He holds a graduate cross appointment in the Department of Microbiology and Immunology at UM. Dr. Rosenblatt is also a member of the Tumor Immunology Program. In the past 20 years, Dr. Rosenblatt has published over 100 journal articles and chapters in the areas of human retroviruses, immune therapies for cancer, and human gene therapy. Dr. Rosenblatt's work has general relevance to breast cancer and he has held major breast cancer grant funding in the past. Prior to his move to Miami, Dr. Rosenblatt served as Chief of the Hematology-Oncology Unit, and had a secondary appointment within the Department of Microbiology and Immunology at the University of Rochester from 1995-2001. Prior to 1995, Dr. Rosenblatt had been a member of the faculty in Hematology Oncology (Associate Professor) and was elected an Associate Member of the Molecular Biology Institute at UCLA, California. Dr Rosenblatt joined University of Miami in 2001, bringing extensive administrative and research experience. He has had continuous NIH and other extramural funding for retroviral, gene therapy and immunotherapy related research since 1986 and has been a standing member of the NCI Experimental Therapeutics II (ET-2) and currently the Clinical Immunology and Immunotherapy II (C-II) study sections. As a Clinician Scientist, his mentorship is of particular importance as SCCC scientist seek to enhance cross talk between our post-PhD and post-MD Fellows in this Breast Cancer Translational Research. His research relevant to Breast Cancer includes the synthesis and testing of novel antibody—fusion proteins which target the HER2 breast cancer antigen, and can inhibit angiogenesis or augment immune response to breast cancer.

E-mail a Friend